Toxicity-evaluation designs for phase I/II cancer immunotherapy trials

Statistics in Medicine

Volumn 29, Issue 7-8, 2010, Pages 712-720

  Messer, Karen ^a   Natarajan, Loki ^a   Ballb, Edward D ^b   Laneb, Thomas A ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Exact confidence interval; MTD; Phase I II clinical trial

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; DRUG EFFICACY; HUMAN; LEUKEMIA; MATHEMATICAL COMPUTING; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RISK ASSESSMENT; TOXICITY TESTING;

BIOSTATISTICS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LIKELIHOOD FUNCTIONS; MAXIMUM TOLERATED DOSE; SAMPLE SIZE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77949342202     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3799     Document Type: Article

References (15)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 2004; 10:909-915.
2. Storer BE. Design and analysis of phase-I clinical-trials. Biometrics 1989; 45:925-937.
3. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. Chapman & Hall, CRC: Boca Raton, FL, 2003.
4. Crowley J, Ankerst D. Handbook of Statistics in Clinical Oncology (2nd edn). Chapman & Hall/CRC, Taylor & Francis Group: Boca Raton, 2006.
5. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. Journal of the National Cancer Institute 2004; 96:990-997.
6. Witten C. FDA and Cancer Vaccine Development. Available from: 'www.fda.gov/cber/summaries/asco0060208cw.pdf' [24 July 2008].
7. Reiner E, Paoletti X, O'Quigley J. Operating characteristics of the standard phase I clinical trial design. Computational Statistics and Data Analysis 1999; 30:303-315.
8. Buoen C, Bjerrum OJ, Thomsen MS. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. Journal of Clinical Pharmacology 2005; 45:1123-1136.
9. Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2001; 2:203-215.
10. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for phase I clinical trials. Biometrics 1997; 53:745-760.
11. Gezmu M, Flournoy N. Group up-and-down designs for dose-finding. Journal of Statistical Planning and Inference 2006; 136:1749-1764.
12. Natarajan L, O'Quigley J. Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples. Statistics in Medicine 2003; 22:1829-1836.
13. O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Statistics in Medicine 1991; 10:1647-1664.
14. Storer BE. Small-sample confidence sets for the Mtd in a phase-I clinical-trial. Biometrics 1993; 49:1117-1125.
15. Grimmet G, Strizaker S. Probability and Random Processes (3rd edn). Oxford University Press: Oxford, 2001.